AI Workflows & Agentic Architecture Directory

Human code reviews miss 60% of bugs and take 4-8 hours on average. AI-powered code review agents catch more issues in minutes, learn from team patterns, and never get tired. Here's why agentic code review is replacing traditional PR reviews in 2026.

VS Code has been the dominant code editor for a decade. But AI-native IDEs like Cursor, Windsurf, and Zed are proving that coding without AI assistance is like driving without power steering — technically possible but increasingly unnecessary. Here's what changed.

AI agents fail silently and unpredictably. Test-driven AI development adds structured testing to agent development — catching regressions, validating behavior, and giving teams confidence that their agents work as intended.

Agent memory is the battleground of 2026. Three approaches compete.

AI safety alignment has evolved from RLHF to Constitutional AI to the 2026 frontier.

Manual code review misses security flaws. This workflow builds pr-guard, a LangGraph pipeline that scans PRs with CodeQL, detects AI-generated vulnerabilities, and suggests automated fixes.

Data pipelines fail silently and teams discover anomalies hours later. This workflow builds pipeline-watch, a LangGraph pipeline with Apache Flink for real-time anomaly detection, automated root cause analysis, and self-healing remediation.

AI agents need to understand time. This MCP server gives agents calendar awareness: check availability, create events, optimize schedules, and prepare meeting briefs from calendar context.

AI inference costs are eating SaaS margins. This deep dive explores the GPU cost crisis, why inference now costs more than training, and 5 strategies to cut costs without cutting quality.

Fine-tuning and prompting are not competing approaches. This deep dive provides a decision framework: when each wins, when to combine them, and the cost-performance tradeoffs.

Drug development takes 10 years and costs $2.6B. AI is cutting that to 3 years and $500M. This deep dive explores how protein folding, molecular generation, and clinical trial optimization are transforming pharmaceutical R&D.

Open-source AI models are competing with proprietary giants. This deep dive analyzes the 2026 landscape: who is winning, what the economics look like, and what open weights mean for the industry.